NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease, announced the approval of inducement share options for eleven new non-executive employees. The grants, totaling 197,000 of NewAmsterdam's ordinary shares, are part of the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $20.03, reflecting the closing market price as of May 1, 2025. The vesting schedule includes 25% of the shares vesting on the one-year anniversary of the vesting commencement date, with the remainder vesting over the following 36 months, contingent on continued service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.